Breaking News Instant updates and real-time market news.

VNDA

Vanda Pharmaceuticals

$27.56

-1.85 (-6.29%)

07:05
12/10/18
12/10
07:05
12/10/18
07:05

Vanda Pharmaceuticals announces 'positive' study results for HETLIOZ

Vanda Pharmaceuticals announced that HETLIOZ improved sleep quality and increased sleep duration in patients with Smith-Magenis Syndrome in a pivotal placebo controlled clinical study. "We are extremely pleased with the results of this study of tasimelteon in patients with Smith-Magenis Syndrome. Tasimelteon was shown to meaningfully improve sleep in SMS patients, addressing an unmet medical need for the most severe symptom constellation of this rare disorder," said Mihael H. Polymeropoulos MD, Vanda's President and Chief Executive Officer. VEC-162-2401 was a double masked 4 week cross-over pivotal clinical trial that studied the effects of tasimelteon versus placebo in 25 patients with SMS. Patients were evaluated for daily diary sleep quality and for daily diary total nighttime sleep duration via a parental post sleep questionnaire. Total nighttime sleep duration was also measured via daily actigraphy. The study had two predefined primary endpoints: DDSQ and DDTST. Tasimelteon met the primary endpoint of improvement in the 50% worst sleep quality and also showed improvement on the primary endpoint of 50% worst total nighttime sleep duration. Tasimelteon demonstrated significant improvement in overall sleep quality and overall total nighttime sleep duration. Tasimelteon improved the overall total nighttime sleep duration by an average of approximately 41 minutes per night, a highly clinically meaningful effect. Given that most of the baseline nights were of shortened sleep duration, tasimelteon also improved sleep duration for the best half of the baseline nights versus placebo. Tasimelteon also showed significant improvement in subjective measures of total nighttime sleep duration via actigraphy, for 50% worst TST and overall TST. In this study, aberrant behaviors improved from baseline on both tasimelteon and placebo but likely due to the relative short duration of the study the differences were not significant between the two groups. In a longer open label study of tasimelteon in SMS, patients were treated for a period of approximately 27 weeks following a 6 week baseline evaluation. In that study, significant improvements from baseline were observed in sleep quality as well as in aberrant behaviors. The improvements in sleep quality and sleep duration demonstrated in the 2401 study were consistent across patients with chromosomal deletions of various lengths as well as a single patient with a point mutation in the RAI1 gene on chromosome 17p. The detailed results are expected to be presented in upcoming meetings and peer reviewed publications.

VNDA Vanda Pharmaceuticals
$27.56

-1.85 (-6.29%)

12/07/18
SBSH
12/07/18
NO CHANGE
Target $47
SBSH
Buy
Vanda Pharmaceuticals price target raised to $47 from $31 at Citi
Citi analyst Joel Beatty raised his price target for Vanda Pharmaceuticals to $47 and keeps a Buy rating on the shares citing the "strong" Phase 2 tradipitant gastroparesis results. The analyst also raised his probability of approval to 65% from 40%.
12/06/18
JMPS
12/06/18
NO CHANGE
Target $52
JMPS
Outperform
Vanda Pharmaceuticals price target raised to $52 from $36 at JMP Securities
JMP Securities analyst Jason Butler raised his price target on Vanda Pharmaceuticals shares to $52 from $36, stating that he now thinks his initial evaluation of the commercial opportunity for tradipitant in gastroparesis may have been overly conservative. He has raised his estimates, primarily driven by a higher assumed cost of therapy, Butler noted. He now projects 2027 sales of $1.8B, assuming an annual net cost of therapy at launch of $8,000, and keeps his estimate of the probability of approval for tradipitant at 70%. Butler maintains an Outperform rating on Vanda shares.
12/04/18
CANT
12/04/18
UPGRADE
Target $43
CANT
Overweight
Cantor sees value in Vanda despite 26% rally, upgrades to Overweight
Cantor Fitzgerald analyst Charles Duncan upgraded Vanda Pharmaceuticals to Overweight from Neutral and raised his price target for the shares to $43 from $26. The analyst is "impressed" with the effect size magnitude for tradipitant in the Phase 2 study in patients with idiopathic and diabetic gastroparesis. This points to a clinically meaningful increase in nausea-free days, indicating a clear improvement in patient quality of life, Duncan tells investors in a research note. The analyst sees value in the shares despite yesterday's 26% rally.
12/04/18
CANT
12/04/18
UPGRADE
CANT
Overweight
Vanda Pharmaceuticals upgraded to Overweight from Neutral at Cantor Fitzgerald

TODAY'S FREE FLY STORIES

MNTA

Momenta

$15.82

-0.21 (-1.31%)

11:14
11/15/19
11/15
11:14
11/15/19
11:14
Hot Stocks
Momenta confirms first patient in the Unity study has delivered a full-term baby »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 16

    Dec

ONTO

Onto Innovation

$35.31

0.97 (2.82%)

11:10
11/15/19
11/15
11:10
11/15/19
11:10
Conference/Events
Onto Innovation management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

LOGM

LogMeln

$73.98

0.77 (1.05%)

11:09
11/15/19
11/15
11:09
11/15/19
11:09
Periodicals
LogMeln in 'deep talks' to sell itself, blog report claims »

LogMeIn is "in deep…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

LK

Luckin Coffee

$23.90

2.37 (11.01%)

11:05
11/15/19
11/15
11:05
11/15/19
11:05
Options
Luckin Coffee call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

BABA

Alibaba

$185.03

2.34 (1.28%)

11:00
11/15/19
11/15
11:00
11/15/19
11:00
Periodicals
Alibaba order books for Hong Kong listing covered 'multiple times,' Reuters says »

Alibaba's $13.4B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

11:00
11/15/19
11/15
11:00
11/15/19
11:00
General news
Today's U.S. reports »

Today's U.S. reports…

TORC

resTORbio

$1.35

-6.58 (-82.98%)

10:51
11/15/19
11/15
10:51
11/15/19
10:51
Downgrade
resTORbio rating change  »

resTORbio downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSN

VeriSign

$186.74

-0.36 (-0.19%)

10:50
11/15/19
11/15
10:50
11/15/19
10:50
Options
Delta neutral call buyers in VeriSign December »

Delta neutral call buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAA

Under Armour

$17.47

0.34 (1.98%)

, UA

Under Armour

$15.76

0.2 (1.29%)

10:47
11/15/19
11/15
10:47
11/15/19
10:47
Hot Stocks
Under Armour says 'always in compliance' with GAAP amid scrutiny »

Under Armour said earlier…

UAA

Under Armour

$17.47

0.34 (1.98%)

UA

Under Armour

$15.76

0.2 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$204.28

-5.605 (-2.67%)

10:40
11/15/19
11/15
10:40
11/15/19
10:40
Options
Nvidia options volume 7x normal as shares whip post earnings »

Nvidia options volume 7x…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 06

    Jan

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

10:30
11/15/19
11/15
10:30
11/15/19
10:30
On The Fly
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

CS

Credit Suisse

$12.98

0.135 (1.05%)

NVDA

Nvidia

$202.92

-6.96 (-3.32%)

OSTK

Overstock.com

$8.30

0.12 (1.47%)

AMD

AMD

$39.05

0.69 (1.80%)

DPW

DPW Holdings

$1.16

-0.06 (-4.92%)

KODK

Kodak

$2.35

-0.02 (-0.84%)

RIOT

Riot Blockchain

$1.53

-0.05 (-3.16%)

TEUM

Pareteum

$0.39

-0.006 (-1.50%)

SRAX

Social Reality

$1.56

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 09

    Dec

  • 06

    Jan

PPL

PPL Corp.

$33.72

0.1 (0.30%)

10:30
11/15/19
11/15
10:30
11/15/19
10:30
Options
Size call spread in PPL Corp reloads short calls »

Size call spread in PPL…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$292.26

2.58 (0.89%)

, HPQ

HP Inc.

$20.13

0.01 (0.05%)

10:29
11/15/19
11/15
10:29
11/15/19
10:29
Recommendations
Netflix, HP Inc., Aramark analyst commentary  »

Gordon Haskett says…

NFLX

Netflix

$292.26

2.58 (0.89%)

HPQ

HP Inc.

$20.13

0.01 (0.05%)

ARMK

Aramark

$43.38

0.08 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

  • 26

    Nov

  • 09

    Dec

  • 10

    Dec

10:25
11/15/19
11/15
10:25
11/15/19
10:25
Conference/Events
Wolfe Research tech strategist to hold analyst/industry webcast »

Tech Strategist…

DTIL

Precision BioSciences

$11.35

-0.45 (-3.81%)

10:25
11/15/19
11/15
10:25
11/15/19
10:25
Conference/Events
Precision BioSciences participates in a conference call with BTIG »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 07

    Dec

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

10:20
11/15/19
11/15
10:20
11/15/19
10:20
Options
Put sale in VIX appears to exit two-week position for 64% gain »

Put sale in VIX appears…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
11/15/19
11/15
10:20
11/15/19
10:20
General news
The September business inventory report undershot estimates »

The September business…

AMRN

Amarin

$22.68

1.19 (5.54%)

10:19
11/15/19
11/15
10:19
11/15/19
10:19
On The Fly
One analyst thinks Amarin could rise toward $50 after positive FDA panel vote »

Shares of Amarin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
11/15/19
11/15
10:17
11/15/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAYS

Paysign

$10.74

-0.53 (-4.70%)

, WAB

Wabtec

$79.36

0.82 (1.04%)

10:16
11/15/19
11/15
10:16
11/15/19
10:16
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

PAYS

Paysign

$10.74

-0.53 (-4.70%)

WAB

Wabtec

$79.36

0.82 (1.04%)

AWK

American Water

$117.25

-0.65 (-0.55%)

RIGL

Rigel Pharmaceuticals

$2.32

0.035 (1.53%)

LPSN

LivePerson

$37.54

1.12 (3.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 25

    Nov

  • 26

    Nov

  • 07

    Dec

  • 10

    Dec

MITK

Mitek Systems

$7.35

-0.35 (-4.55%)

, AGCO

Agco

$80.01

-0.11 (-0.14%)

10:16
11/15/19
11/15
10:16
11/15/19
10:16
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

MITK

Mitek Systems

$7.35

-0.35 (-4.55%)

AGCO

Agco

$80.01

-0.11 (-0.14%)

GPOR

Gulfport Energy

$2.84

-0.26 (-8.39%)

CNP

CenterPoint Energy

$25.31

-1.37 (-5.13%)

NVDA

Nvidia

$204.18

-5.7 (-2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 13

    Dec

  • 06

    Jan

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
11/15/19
11/15
10:16
11/15/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$92.55

2.07 (2.29%)

, AMAT

Applied Materials

$61.45

4.56 (8.02%)

10:16
11/15/19
11/15
10:16
11/15/19
10:16
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

QCOM

Qualcomm

$92.55

2.07 (2.29%)

AMAT

Applied Materials

$61.45

4.56 (8.02%)

GRUB

GrubHub

$38.99

0.47 (1.22%)

BCRX

BioCryst

$1.65

0.07 (4.43%)

NVDA

Nvidia

$204.69

-5.19 (-2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 02

    Dec

  • 09

    Dec

  • 09

    Dec

  • 06

    Jan

  • 14

    Nov

AM

Antero Midstream

$5.34

-0.035 (-0.65%)

10:15
11/15/19
11/15
10:15
11/15/19
10:15
Options
Antero Midstream put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
11/15/19
11/15
10:10
11/15/19
10:10
General news
U.S. business inventories were flat in September, with sales slipping -0.2% »

U.S. business inventories…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.